Entrada Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Entrada Therapeutics (Nasdaq: TRDA), a clinical-stage biopharmaceutical company focused on developing medicines for intracellular targets, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. CEO Dipal Doshi will deliver a presentation on Wednesday, January 15, 2025, at 11:15 a.m. PT (2:15 p.m. ET).
The presentation will be accessible via live webcast on the company's Investor Relations website, with a replay available for 30 days following the event. Entrada's mission centers on transforming patient lives by creating innovative treatments that can reach previously inaccessible intracellular targets.
Positive
- None.
Negative
- None.
News Market Reaction – TRDA
In the trading session that priced this news, TRDA declined 7.32%, reflecting a notable negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets long considered inaccessible. The Company today announced that Dipal Doshi, Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 11:15 a.m. PT (2:15 p.m. ET).
A live webcast will be available on the Presentations portion of Entrada’s Investor Relations website at https://ir.entradatx.com. The webcast will be archived and available for replay for 30 days after the event.
About Entrada Therapeutics
Entrada Therapeutics is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company’s Endosomal Escape Vehicle (EEV™)-therapeutics are designed to enable the efficient intracellular delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Through this proprietary, versatile and modular approach, Entrada is advancing a robust development portfolio of RNA-, antibody- and enzyme-based programs for the potential treatment of neuromuscular, ocular, metabolic and immunological diseases, among others. The Company’s lead oligonucleotide programs are in development for the potential treatment of people living with Duchenne who are exon 44, 45 and 50 skipping amenable. Entrada has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.
For more information about Entrada, please visit our website, www.entradatx.com, and follow us on LinkedIn.
Investor and Media Contact
Caileigh Dougherty
Head of Investor Relations & Corporate Communications
cdougherty@entradatx.com
